Rahul Khara Increases Stake in Disc Medicine, Inc. (IRON)

Rahul Khara, the Chief Legal Officer of Disc Medicine, Inc. (NASDAQGM: IRON), purchased 851 shares of the company on June 26, 2026. The shares were bought at an average price of $14.69, totaling approximately $12,501. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Disc Medicine, Inc.

On June 26, 2026, Rahul Khara acquired 851 shares of Disc Medicine at $14.69 each, totaling around $12,501. This purchase was not under a Rule 10b5-1 plan. Additionally, on the same day, Khara sold 851 shares at $75.00 per share, which was a planned transaction.

Other Institutional Activity in Disc Medicine

Several institutional investors adjusted their positions in Disc Medicine recently. FMR LLC increased its holdings by 136,672 shares, ending with 5,586,894 shares valued at about $357.23 million, a 2.5% increase. RA Capital Management, L.P. added 474,089 shares, resulting in 2,450,221 shares valued at $156.67 million, marking a 24% increase. Meanwhile, BlackRock, Inc. slightly reduced its stake by 1,149 shares, holding 2,273,831 shares worth $145.39 million, a 0.1% decrease. Wellington Management Group LLP boosted its position by 217,102 shares, now holding 1,735,376 shares valued at $110.96 million, a 14.3% increase. State Street Corp significantly increased its holdings by 510,253 shares, ending with 1,698,244 shares worth $108.59 million, a 43% increase.

Disc Medicine, Inc. Stock Down 7.0%

Shares of Disc Medicine, Inc. (NASDAQGM: IRON) traded near $74.5 on Wednesday. The company has a market capitalization of approximately $2.86 billion. It currently does not have a meaningful P/E ratio as it is not profitable, with a forward P/E of -9.86. The stock's beta is 2.101, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from $40.00 to $99.50, with a 50-day moving average of $68.82 and a 200-day moving average of $73.42. Disc Medicine maintains a strong liquidity position with a current ratio of 24.00 and a quick ratio of 23.45, while its debt-to-equity ratio stands at 4.51.

Analysts Set New Price Targets

Analysts remain optimistic about Disc Medicine, maintaining a strong buy consensus. On June 16, 2026, Morgan Stanley maintained its buy rating with a price target of $85.00. The consensus target price is $101.55, based on 11 analyst opinions.

About Disc Medicine, Inc.

Disc Medicine, Inc. is a biotechnology company based in Watertown, Massachusetts. Founded in 2017, it focuses on discovering, developing, and commercializing novel treatments for serious blood disorders. The company's pipeline includes several clinical and preclinical candidates targeting red blood cell formation and function, primarily through heme biosynthesis and iron homeostasis. Its lead products aim to treat conditions like erythropoietic porphyrias, anemia of myelofibrosis, and polycythemia vera. Dr. John D. Quisel, Esq., J.D., Ph.D., serves as CEO of the company, which employs 154 people.

Bottom Line

Rahul Khara's recent purchase of Disc Medicine shares reflects his confidence in the company's future. Institutional investors have also shown interest, with several increasing their stakes. While the company is not yet profitable, analysts maintain a strong buy rating, anticipating positive developments in its pipeline. As always, remember that insider transactions and analyst ratings are backward-looking and not necessarily indicative of future performance.